Search research articles
Contact Us
Filters
Showing results (1-10 of 50) with videos related to
Page
of 5
Sort By:
Harefuah
|
July 28, 2009
[Controlled release melatonin (Circadin) in the treatment of insomnia in older patients: efficacy and safety in patients with history of use and non-use of hypnotic drugs]
Nava Zisapel
Expert Opinion on Investigational Drugs
|
November 26, 2014
Current Phase II investigational therapies for insomnia
Nava Zisapel
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society
|
August 15, 2016
Paediatric use of melatonin: Letter to the Editor regarding the manuscript "Current role of melatonin in pediatric neurology:Clinical recommendations" by Bruni et al. Eur J Paediatr Neurol. 2015 Mar;19(2):122-33
Nava Zisapel
British Journal of Pharmacology
|
January 11, 2018
New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation
Nava Zisapel
Journal of Paediatrics and Child Health
|
July 31, 2015
Safety of melatonin
Nava Zisapel
Expert Opinion on Emerging Drugs
|
June 12, 2012
Drugs for insomnia
Nava Zisapel
Expert Review of Clinical Pharmacology
|
March 14, 2022
Assessing the potential for drug interactions and long term safety of melatonin for the treatment of insomnia in children with autism spectrum disorder
Nava Zisapel
Human Brain Mapping
|
December 21, 2007
Late evening brain activation patterns and their relation to the internal biological time, melatonin, and homeostatic sleep debt
Tali Gorfine, Nava Zisapel
Expert Opinion on Pharmacotherapy
|
March 21, 2012
Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia
Patrick Lemoine, Nava Zisapel
Journal of Medicinal Chemistry
|
August 13, 2009
A novel decoy that interrupts G93A-superoxide dismutase gain of interaction with malate dehydrogenase improves survival in an amyotrophic lateral sclerosis cell model
Yael Mali, Nava Zisapel
Page
of 5
Search research articles
Search
Showing results (1-10 of 50) with videos related to
Sort By:
Page
of 5
Harefuah
|
July 28, 2009
[Controlled release melatonin (Circadin) in the treatment of insomnia in older patients: efficacy and safety in patients with history of use and non-use of hypnotic drugs]
Nava Zisapel
Expert Opinion on Investigational Drugs
|
November 26, 2014
Current Phase II investigational therapies for insomnia
Nava Zisapel
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society
|
August 15, 2016
Paediatric use of melatonin: Letter to the Editor regarding the manuscript "Current role of melatonin in pediatric neurology:Clinical recommendations" by Bruni et al. Eur J Paediatr Neurol. 2015 Mar;19(2):122-33
Nava Zisapel
British Journal of Pharmacology
|
January 11, 2018
New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation
Nava Zisapel
Journal of Paediatrics and Child Health
|
July 31, 2015
Safety of melatonin
Nava Zisapel
Expert Opinion on Emerging Drugs
|
June 12, 2012
Drugs for insomnia
Nava Zisapel
Expert Review of Clinical Pharmacology
|
March 14, 2022
Assessing the potential for drug interactions and long term safety of melatonin for the treatment of insomnia in children with autism spectrum disorder
Nava Zisapel
Human Brain Mapping
|
December 21, 2007
Late evening brain activation patterns and their relation to the internal biological time, melatonin, and homeostatic sleep debt
Tali Gorfine, Nava Zisapel
Expert Opinion on Pharmacotherapy
|
March 21, 2012
Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia
Patrick Lemoine, Nava Zisapel
Journal of Medicinal Chemistry
|
August 13, 2009
A novel decoy that interrupts G93A-superoxide dismutase gain of interaction with malate dehydrogenase improves survival in an amyotrophic lateral sclerosis cell model
Yael Mali, Nava Zisapel
Page
of 5